Evaluate the Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemic

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

335

Participants

Timeline

Start Date

November 24, 2023

Primary Completion Date

October 30, 2024

Study Completion Date

September 27, 2025

Conditions

Hyperlipidemic

Interventions

DRUG

SHR-1918

DRUG

SHR-1918 placebo

Trial Locations (1)

The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou

All Listed Sponsors

lead

Beijing Suncadia Pharmaceuticals Co., Ltd

INDUSTRY

NCT06109831 - Evaluate the Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemic | Biotech Hunter | Biotech Hunter